Nonalcoholic hepatic steatosis in Zucker diabetic rats: Spontaneous evolution and effects of metformin and fenofibrate

Obesity

Volumn 17, Issue 7, 2009, Pages 1381-1389

  Forcheron, Fabien ^a   Abdallah, Pauline ^a   Basset, Alexandra ^b   Del Carmine, Peggy ^b   Haffar, Ghina ^a   Beylot, Michel ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RATTUS;

EID: 67649829768     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.661     Document Type: Article

References (46)

1. Browning JD, Szczepanlak LS, Dobbins R et al. Prevalence of hepatic steatosis In an urban population In the United States: Impact of ethnicity, Hepatology 2004 ;40:1387-1395,
2. Marcheslnl G, Marzocchl R, Agostlnl F, Buglanesl E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427
3. Matteoni CA, Younossl ZM, Gramlich T et al. Nonalocoholic fatty liver disease: a spectrum of clinical pathological severity, Gastroenterology 1999;116:1413-1419.
4. McCullough A, Thiazolidinediones for nonalcoholic steatohepatitis, promising but not ready for prime time. N Engl J Med 2006;355:2361 -2363.
5. Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalocoholic fatty liver disease: an overview of current Insights In pathogenesis, diagnosis and treatment, World J Gastroenterol 2008;14:2474-2486
6. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferatorsactivated receptors In the pathogenesis and treatment of nonalcoholic fatty liver disease, World J Gastroenterol 2008;14:22-28.
7. Harano Y, Yasul K, Toyama T et al. Fenofibrate, a ppar alpha agonist reduces hepatic steatosis and lipid peroxidation In fatty liver Shionogi mice with hereditary fatty liver, Liver lnt 2006;26:613-620
8. Kim H, Haluzik M, Asghar Z et al. PPAR-alpha agonist treatment In a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis, Diabetes 2003;52:1770-1778
9. Zang M, Zuccollo A, Hou X et al. AMP-activated protein kinase is required for the lipld-lowering effect of metformin in insulin-resistant human HepG2 cells, J Biol Chem 2004;279:47898-47905
10. Lin HZ, Yang SQ, Chuckaree C et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice, Nat Med 2000;6:998-1003
11. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082-1090.
12. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perillo RP. Metformin in the treatment of non-alcoholic steatohepatltls: a pilot open label trial. Aliment Pharmacol Ther 2004;20:23-28.
13. Duseja A, Das A, Dhlman RK et al. Metformin is effective in achieving biochemical response In patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle Interventions, Ann Hepatol 2007;6:222-226.
14. Nobili V, Manco M, Clampalini P et al. Metformin use In children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008;30:1168-1176.
15. Yasuda N, Inoue T, Nagakura T et al. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptyl peptidase IV inhibitor In Zucker fa/fa rats, J Pharmacol Exp Ther 2004;310:614-619.
16. Etgen GJ, Oldham BA. Profilling of Zucker diabetic fatty rats In their progression to the overt diabetic state, Metabolism 2000;49:684-688
17. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride and cholesterol-lowering effect of fenofibrate in hyperlipidemlc type 2 diabetic patients, Diabetes 2002;51:3486-3491.
18. Letexier D. Plnteur C. Large V. Frering V. Beylot M. Comparison of the expression and activity of the lipogenio pathway in human and rat adipose tissue, J Lipid Res 2003;44:2127-2134
19. Chirieac D. Collins H. Ciancl J. Sparks J. Sparks C. Altered triglyceridrich lipoprotein production In Zucker diabetic fatty rats, Am J Physiol 2004;287:E42-E49
20. Suh YH. Kim Y. Bang JH et al. Analysis of gene expression profiles in insulinsensitive tissues from pre-dlabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol 2005;34:299-315.
21. Diraison F. Beylot M. Role of human liver lipogenesis and reesterification In triglycerides In triglycerides secretion and In FFA reesterification. Am J Physiol 1998;274:E321-E327.
22. Diraison F. Beylot M. Moulin P. Contribution of hepatic de novo lipogenesis and reesteriflcatlon of plasma NEFA to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003;29:1-8
23. Tamura S. Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalocohollc fatty liver disease, J Clin Invest 2005;115:1139-1142
24. Donnelly K. Smith C. Schwarzenberg S et al. Sources of fatty acids stored In liver and secreted via lipoproteins In patients with nonalocoholic fatty liver disease, J Clin Invest 2005; 115:1343-1351
25. Girard J. Perdereau P. Foufelle F. Prip-Buus C. Ferre P. Regulation of lipogenic enzyme genes expression by nutrients and hormones. FASEB J 1994;8:36-42.
26. McGarry JD. Foster DW. Regulation of hepatic fatty acids oxidation and ketone body production, Ann Rev Biochem 1980;49:395-411.
27. Foufelle F. Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1 c. Biochem J 2002;366:377-391.
28. Uyeda K. Yamashita H. Kawaguchi T. Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage, Biochem Pharmacol 2002;63:13476-13478.
29. Kakuma T. Lee Y. Higa M et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins In liver and pancreatic islets. Proc Natl Acad Sci USA 2000;97:8536-8541
30. Takaishi K. Duplomb L. Wang M. Li J. Unger R. Hepatic insig-1 or -2 overexpression reduces lipogenesis In obese Zucker diabetic rats and in fasted/refed normal rats, Proc Natl Acad Sci USA 2004;101:7106-7111
31. Tacken PJ. Hofker Mh. Havekes LM. van Dijk KW, Living up to a name: the role of the VLDL receptor In lipid metabolism, Curr Opin Lipidol 2001;12:275-279.
32. Wahren J, Sato Y. Ostman J. Hagenfeldt L. Felig P. Turnover and splanchnic metabolism of free fatty acids and ketones In insulindependent diabetics at rest and In response to exercise, J Clin Invest 1984;73:1367-1376.
33. Tietge U. Bakillah A. Maugeais C et al. Hepatic overexpresslon of microsomal triglyceride transfer protein (MTP) results In increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 1999;40: 2134-2139.
34. Dentin R. Pégorier J. Benhamed F et al. Hepatic glucoklnase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lilpogenic gene expression, J Biol Chem 2004:279: 20314-20326.
35. He Z. Jiang T. Wang Z. Levi M. Li J., Modulation of carbohydrate response element-binding protein ChREBP gene expression In 3T3-L1 adipocyte and rat adipose tissue. Am J Physiol Endocrinol Metab 2004;287: E424-E430.
36. Zhou G. Myers R. Li Y et al. Role of AMP activated protein kinase in mechanism of metformin action, J Clin Invest 2001 ;108:1167-1174
37. Schwimmer JB. Mlddleton MS. Deutsch R. Lavine JE, A phase 2 clinical trial of metformin as a treatment for non-diabetic paedlatric non-alcoholic steatohepatitis, Aliment Pharmacol Ther 2005;21 : 871-879.
38. Tlikkainen M. Häkkinen AM. Korshenlnnlkova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
39. Srivastava R. Jahagirdar R. Aznar S. Sharma S. Bisgaler C. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptordeficient mice, Mol Cell Biochem 2006;285:35-50
40. Améen C. Edvardsson U. Ljungberg A et al. Activation of PPAR alpha increases the expression and activity of MTP In liver. J Biol Chem 2005;280:1224-1229
41. Edvardsson U. Ljungberg A. Linden D et al. PPAR alpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. J Lipid Res 2006;47:329-340.
42. Kesänleml YA. Grundy SM. influence of gemfibrozil and Clofibrate on metabolism of cholesterol and plasma triglycerides in man, JAMA 1984;251:2241-2246
43. Petit D, Bonnefis MT. Rey C. infante R. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atheroscierosis 1988;74:215-225.
44. Deushl M. Nomura M. Kawakami A et al. Ezetimibe improves liver steatosis and insulin resistance In obese rat model of metabolic syndrome. FESS Lett 2007;581:5664-5670.
45. Tobbli J. Munöz M. Cao G et al. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis In obese Zucker rats, Obesity 2008; 16: 770-776.
46. Gary-Bobo M. Elachouri G. Gallas JF et al. Rilmonabant reduces obesityassociated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology 2007;46:122-129.